Manufacturers must navigate complex regulatory landscapes, understand diverse cultural nuances, and prioritize patient access in each region.
Thomas Ruggia
Advertisement
President and CEO, Samsara Vision
Articles by Thomas Ruggia
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
3
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
4
Is FDA Streamlining Regulations in the Biosimilar Space?
5
